Faheez Mohamed
Faheez Mohamed has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Villeneuve
Service de Chirurgie Digestive et Oncologique , Hôpital Lyon Sud, Hospices Civils de Lyon , Lyon , France
3 shared publications - Olivier Glehen
Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France; CICLY, Lyon 1 University, France
3 shared publications - Aditi Bhatt
Department of Surgical Oncology, Shalby Cancer and Research Institute, Shalby Hospital, Ahmedabad, India
2 shared publications Almog Ben Yacov
Surgical Oncology, Sheba Medical Center, Tel Hashomer, Israel
2 shared publicationsAnwar Alshukami
Radiology, King Khaled Hospital, Najran, Saudi Arabia
2 shared publications- Armando Sardi
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD 21202-2001 USA
2 shared publications
Latest Publications
- 11 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 8585-8595
Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
The presence at diagnosis, or development of, colorectal peritoneal metastases (CPM) is common in colorectal cancer. Cytoreductive surgery (CRS) and hypert
- 11 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (13) , 8585-8595
Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
The presence at diagnosis, or development of, colorectal peritoneal metastases (CPM) is common in colorectal cancer. Cytoreductive surgery (CRS) and hypert
- Open Access
Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study
Introduction Despite optimal patient selection and surgical effort, recurrence is seen in over 70% of patients undergoing cytoreductive surgery (CRS) for peritoneal metastases (PM). Apart from the Peritoneal Cancer Index (PCI), completeness of cytoreduction and tumour grade, there are other factors like disease distribution in the peritoneal cavity, pathological response to systemic chemotherapy (SC), lymph node metastases and morphology of PM which may have prognostic value. One reason for the underutilisation of these factors is that they are known only after surgery. Identifying clinical predictors, specifically radiological predictors, could lead to better utilisation of these factors in clinical decision making and the extent of peritoneal resection performed for different tumours. This study aims to study these factors, their impact on survival and identify clinical and radiological predictors. Methods and analysis There is no therapeutic intervention in the study. All patients with biopsy-proven PM from colorectal, appendiceal, gastric and ovarian cancer and peritoneal mesothelioma undergoing CRS will be included. The demographic, clinical, radiological, surgical and pathological details will be collected according to a prespecified format that includes details regarding distribution of disease, morphology of PM, regional node involvement and pathological response to SC. In addition to the absolute value of PCI, the structures bearing the largest tumour nodules and a description of the morphology in each region will be recorded. A correlation between the surgical, radiological and pathological findings will be performed and the impact of these potential prognostic factors on progression-free and overall survival determined. The practices pertaining to radiological and pathological reporting at different centres will be studied. Ethics and dissemination The study protocol has been approved by the Zydus Hospital ethics committee (27 July, 2020) and Lyon-Sud ethics committee (A15-128). Trial registration number CTRI/2020/09/027709; Pre-results.
Open AccessPatterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study
Introduction Despite optimal patient selection and surgical effort, recurrence is seen in over 70% of patients undergoing cytoreductive surgery (CRS) for peritoneal metastases (PM). Apart from the Peritoneal Cancer Index (PCI), completeness of cytoreduction and tumour grade, there are other factors like disease distribution in the peritoneal cavity, pathological response to systemic chemotherapy (SC), lymph node metastases and morphology of PM which may have prognostic value. One reason for the underutilisation of these factors is that they are known only after surgery. Identifying clinical predictors, specifically radiological predictors, could lead to better utilisation of these factors in clinical decision making and the extent of peritoneal resection performed for different tumours. This study aims to study these factors, their impact on survival and identify clinical and radiological predictors. Methods and analysis There is no therapeutic intervention in the study. All patients with biopsy-proven PM from colorectal, appendiceal, gastric and ovarian cancer and peritoneal mesothelioma undergoing CRS will be included. The demographic, clinical, radiological, surgical and pathological details will be collected according to a prespecified format that includes details regarding distribution of disease, morphology of PM, regional node involvement and pathological response to SC. In addition to the absolute value of PCI, the structures bearing the largest tumour nodules and a description of the morphology in each region will be recorded. A correlation between the surgical, radiological and pathological findings will be performed and the impact of these potential prognostic factors on progression-free and overall survival determined. The practices pertaining to radiological and pathological reporting at different centres will be studied. Ethics and dissemination The study protocol has been approved by the Zydus Hospital ethics committee (27 July, 2020) and Lyon-Sud ethics committee (A15-128). Trial registration number CTRI/2020/09/027709; Pre-results.
- Open Access
Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumors treated by cytoreductive surgery: Study protocol of a prospective, multi-center, observational study
Introduction: Despite optimal patient selection and surgical effort, recurrence is seen in over 70% of patients undergoing cytoreductive surgery(CRS) for peritoneal metastases (PM). Apart from the peritoneal cancer index(PCI), completeness of cytoreduction and tumor grade, there are other factors like disease distribution in the peritoneal cavity, pathological response to systemic chemotherapy(SC), lymph node metastases and morphology of PM which may have prognostic value. One reason for the underutilization of these factors is that they are known only after surgery. Identifying clinical predictors, specifically radiological predictors, could lead to better utilization of these factors in clinical decision making and the extent of peritoneal resection performed for different tumors. This study aims to study these factors, their impact on survival and identify clinical and radiological predictors. Methods and analysis: There is no therapeutic intervention in the study. All patients with biopsy proven PM from colorectal, appendiceal, gastric and ovarian cancer and peritoneal mesothelioma undergoing CRS will be included. The demographic, clinical, radiological, surgical and pathological details will be collected according to a pre-specified format that includes details regarding distribution of disease, morphology of PM, regional node involvement and pathological response to SC. In addition to the absolute value of PCI, the structures bearing the largest tumor nodules and a description of the morphology in each region will be recorded. A correlation between the surgical, radiological and pathological findings will be performed and the impact of these potential prognostic factors on progression-free and overall survival determined. The practices pertaining to radiological and pathological reporting at different centers will be studied. Ethics and dissemination: The study protocol has been approved by the Zydus Hospital ethics committee (27 th July, 2020) and Lyon-sud ethics committee (A15-128). It is registered with the clinical trials registry of India (CTRI/2020/09/027709). The results will be published in peer-reviewed scientific journals. Strength and limitations: A prospective correlation between the radiological, surgical and pathological findings in patients undergoing CRS will be performed which has not been done before. Being prospective in nature it will also enable us to evaluate the impact of the current treatment practices on the clinical end-points There is fixed protocol for radiological and pathological evaluation for which there are no specific guidelines The data collection format will capture all the relevant data but this may affect compliance. Despite the large sample size planned for each primary site, the heterogeneity of treatment protocols may be a limiting factor while evaluating the impact on survival.
Open AccessPatterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumors treated by cytoreductive surgery: Study protocol of a prospective, multi-center, observational study
Introduction: Despite optimal patient selection and surgical effort, recurrence is seen in over 70% of patients undergoing cytoreductive surgery(CRS) for peritoneal metastases (PM). Apart from the peritoneal cancer index(PCI), completeness of cytoreduction and tumor grade, there are other factors like disease distribution in the peritoneal cavity, pathological response to systemic chemotherapy(SC), lymph node metastases and morphology of PM which may have prognostic value. One reason for the underutilization of these factors is that they are known only after surgery. Identifying clinical predictors, specifically radiological predictors, could lead to better utilization of these factors in clinical decision making and the extent of peritoneal resection performed for different tumors. This study aims to study these factors, their impact on survival and identify clinical and radiological predictors. Methods and analysis: There is no therapeutic intervention in the study. All patients with biopsy proven PM from colorectal, appendiceal, gastric and ovarian cancer and peritoneal mesothelioma undergoing CRS will be included. The demographic, clinical, radiological, surgical and pathological details will be collected according to a pre-specified format that includes details regarding distribution of disease, morphology of PM, regional node involvement and pathological response to SC. In addition to the absolute value of PCI, the structures bearing the largest tumor nodules and a description of the morphology in each region will be recorded. A correlation between the surgical, radiological and pathological findings will be performed and the impact of these potential prognostic factors on progression-free and overall survival determined. The practices pertaining to radiological and pathological reporting at different centers will be studied. Ethics and dissemination: The study protocol has been approved by the Zydus Hospital ethics committee (27 th July, 2020) and Lyon-sud ethics committee (A15-128). It is registered with the clinical trials registry of India (CTRI/2020/09/027709). The results will be published in peer-reviewed scientific journals. Strength and limitations: A prospective correlation between the radiological, surgical and pathological findings in patients undergoing CRS will be performed which has not been done before. Being prospective in nature it will also enable us to evaluate the impact of the current treatment practices on the clinical end-points There is fixed protocol for radiological and pathological evaluation for which there are no specific guidelines The data collection format will capture all the relevant data but this may affect compliance. Despite the large sample size planned for each primary site, the heterogeneity of treatment protocols may be a limiting factor while evaluating the impact on survival.
- 1 July 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (7) , 1035-1041
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours
- 1 July 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (7) , 1035-1041
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours
- 1 June 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (6) , 877-882
A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application
- 1 June 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (6) , 877-882
A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application
Acute appendicitis: Leaving normal looking appendices
Footnotes Competing interests None declared.